HIV Infection Clinical Trial
Official title:
A Multicenter, Open Label, Non-Comparative Safety Study Of Maraviroc
Verified date | September 2011 |
Source | ViiV Healthcare |
Contact | n/a |
Is FDA regulated | No |
Health authority | Brazil: National Ethics Committee (CONEP) |
Study type | Interventional |
To collect safety and tolerability data in a more diverse patient population of patients with HIV/Aids, who have limited therapeutic options.
Status | Completed |
Enrollment | 209 |
Est. completion date | September 2010 |
Est. primary completion date | August 2010 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Subjects with limited or no approved treatment options available to them due to resistance or intolerance; - Subjects must be failing to achieve adequate virologic suppression on their current regimen and have HIV-1 RNA = 1000 copies/ml, at screening. - Have only R5 HIV-1 at Screening as verified by the Monogram Biosciences Trofile assay. Exclusion Criteria: - Failed prior treatment with any CCR5 antagonist, in any ongoing CCR5 trials or having previously discontinued Maraviroc in trials - Potentially life threatening (Grade 4) laboratory abnormality or medical condition (according to the Division of AIDS table for grading severity of adult adverse experiences) still under investigation unless a diagnosis has been established and felt not to affect risk/benefit assessment or eventual interpretation of safety results, based on discussion between the investigator and Pfizer. |
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Brazil | Pfizer Investigational Site | Belo Horizonte | MG |
Brazil | Pfizer Investigational Site | Brasilia | DF |
Brazil | Pfizer Investigational Site | Campinas | SP |
Brazil | Pfizer Investigational Site | Campinas | SP |
Brazil | Pfizer Investigational Site | Curitiba | PR |
Brazil | Pfizer Investigational Site | Florianopolis | SC |
Brazil | Pfizer Investigational Site | Nova Iguaçu | RJ |
Brazil | Pfizer Investigational Site | Porto Alegre | RS |
Brazil | Pfizer Investigational Site | Ribeirao Preto | SP |
Brazil | Pfizer Investigational Site | Salvador | BA |
Brazil | Pfizer Investigational Site | Santo Andre | SP |
Brazil | Pfizer Investigational Site | Sao Paulo | SP |
Brazil | Pfizer Investigational Site | Sao Paulo | SP |
Brazil | Pfizer Investigational Site | Sao Paulo | SP |
Brazil | Pfizer Investigational Site | Sao Paulo | SP |
Brazil | Pfizer Investigational Site | São Paulo | SP |
Lead Sponsor | Collaborator |
---|---|
ViiV Healthcare | Pfizer |
Brazil,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants With Grade 3 and Grade 4 Adverse Events (AEs) and Serious Adverse Events (SAEs) | AEs: any untoward medical occurrence/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was congenital anomaly. Grade 3: Events that interrupted participant's usual daily activity and traditionally required systemic drug therapy or other treatment. Grade 4: Events which were unacceptable and intolerable or which were irreversible or caused participant to be in imminent danger of death. | Baseline to 30 days post-week 96 or early termination (ET) | Yes |
Primary | Number of Participants With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 and Grade 4 Laboratory Abnormalities | Grade 3 or severe events included those that interrupted participant's usual daily activity and traditionally required systemic drug therapy or other treatment. Grade 4 or very severe events included those that were unacceptable and intolerable or which were irreversible or caused the participant to be in imminent danger of death. | Baseline to 30 days post-week 96 or ET | Yes |
Primary | Number of Participants With Treatment Emergent Malignancies | Baseline to 30 days post-week 96 or ET | Yes | |
Primary | Number of Participants With Category C Acquired Immunodeficiency Syndrome (AIDS) Related Infections | Number of participants with AIDS-related infections based on investigator classification guided by a predefined list of clinical Category C AEs per Center for Disease Control (CDC) HIV Classification System. | Baseline to 30 days post-week 96 or ET | Yes |
Primary | Number of Participants With Laboratory Test Abnormalities | Pre-defined criteria based on upper limit normal (ULN) and lower limit normal (LLN) were established for each laboratory test to define the values that would be identified as laboratory test abnormality. | Baseline to 30 days post-week 96 or ET | Yes |
Secondary | Percentage of Participants With at Least 0.5 Log 10 Reduction in Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) | Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84 and Week 96 or end of treatment (EOT) | No | |
Secondary | Percentage of Participants With at Least 1.0 Log 10 Reduction in HIV-1 RNA | Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84 and Week 96 or EOT | No | |
Secondary | Percentage of Participants Achieving HIV-1 RNA Below Limit of Quantification | Below limit of quantification was defined as less than 400 copies/milliliter (mL) | Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84 and Week 96 or EOT | No |
Secondary | Change From Baseline in Lymphocyte Cluster of Differentiation 4 (CD4) Count at Week 4, 8, 12, 24, 36, 48, 60, 72, 84 and Week 96 or EOT | Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84 and Week 96 or EOT | No | |
Secondary | Change From Baseline in Lymphocyte Cluster of Differentiation 8 (CD8) Count at Week 4, 8, 12, 24, 36, 48, 60, 72, 84 and Week 96 or EOT | Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84 and Week 96 or EOT | No | |
Secondary | Change From Baseline in CD4 Percent at Week 4, 8, 12, 24, 36, 48, 60, 72, 84 and Week 96 or EOT | Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84 and Week 96 or EOT | No | |
Secondary | Change From Baseline in CD8 Percent at Week 4, 8, 12, 24, 36, 48, 60, 72, 84 and Week 96 or EOT | Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84 and Week 96 or EOT | No | |
Secondary | Number of Participants With C-X-C Chemokine Receptor Type 4 {CXCR4} [X4] Tropism Status | Virus tropism was done by the Monogram Biosciences Trofile assay. | Time of virologic failure (VF) and Week 96 or EOT | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02135419 -
Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions
|
Phase 3 | |
Active, not recruiting |
NCT02663856 -
My Smart Age With HIV: Smartphone Self-assessment of Frailty
|
||
Completed |
NCT02659306 -
Metformin Immunotherapy in HIV Infection
|
Phase 1 | |
Terminated |
NCT02743598 -
Liraglutide for HIV-associated Neurocognitive Disorder
|
Phase 4 | |
Completed |
NCT02663869 -
Aging With HIV at Younger vs Older Age: a Diverse Population With Distinct Comorbidity Profiles
|
||
Completed |
NCT02846402 -
Impact of HIV Self-testing Among Female Sex Workers in Kampala, Uganda
|
N/A | |
Completed |
NCT02921516 -
Growing Up: Intervening With HIV-Positive Adolescents in Resource-Poor Settings
|
N/A | |
Completed |
NCT02564341 -
Targeting Effective Analgesia in Clinics for HIV - Intervention
|
N/A | |
Active, not recruiting |
NCT02302950 -
A Retrospective Analysis of Raltegravir Use in Minority HIV Infected Women in Houston, Texas
|
N/A | |
Terminated |
NCT02109224 -
Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection
|
Phase 1 | |
Completed |
NCT01852942 -
Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV
|
Phase 2 | |
Completed |
NCT02269605 -
Bryostatin-1 Effect on HIV-1 Latency and Reservoir in HIV-1 Infected Patients Receiving Antiretroviral Treatment
|
Phase 1 | |
Completed |
NCT01830595 -
Lactoferrin Treatment in HIV Patients
|
Phase 2 | |
Terminated |
NCT01902186 -
Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir
|
Phase 4 | |
Completed |
NCT02527135 -
Text Messaging to Improve HIV Testing Among Young Women in Kenya
|
N/A | |
Completed |
NCT02118168 -
Observational Study for the Extended Follow-up of the Patients Enrolled in the Therapeutic Clinical Trial ISS T-002
|
N/A | |
Completed |
NCT02525146 -
Birmingham Access to Care Study
|
N/A | |
Completed |
NCT01946217 -
Factors Affecting Patient Participation in AIDS Malignancy Clinical Trials Consortium Clinical Trials
|
N/A | |
Active, not recruiting |
NCT02602418 -
Neural Correlates of Working Memory Training for HIV Patients
|
N/A | |
Completed |
NCT01805427 -
Antiretroviral Therapy and Extreme Weight
|
N/A |